GlassScriptPhysician profile
Maya Kommineni
NPI 1578721379
$3,575.46
in general payments reported to CMS, 2019-2025
23 companies · $326 in 2025
The $326 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $150 · 2021: $692 · 2022: $594 · 2023: $388 · 2024: $204 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.59 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $529.97 | 2019-2022 | |
| Boston Scientific Corporation | $529.42 | 2019-2023 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $504.91 | 2019-2025 | |
| Amgen INC. | $279.07 | 2019-2022 | |
| Abbott Laboratories | $245.60 | 2019-2025 | Cardiomems |
| Lantheus Medical Imaging, INC. | $209.69 | 2019-2024 | Definity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $202.81 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $160.30 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $143.63 | 2019-2023 | Brilinta |
| Novo Nordisk INC | $125.00 | 2022 | |
| Inari Medical, INC. | $122.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.36 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $89.18 | 2019-2021 | |
| Pfizer INC. | $59.43 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $54.76 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $43.13 | 2023 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $39.18 | 2019-2025 | Eliquis |
| Actelion Pharmaceuticals US, INC. | $38.15 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $25.57 | 2019 | |
| Cvrx, INC. | $23.72 | 2024 | Barostim Neo System |
| Vifor Pharma, INC. | $18.32 | 2019 | |
| Edwards Lifesciences Corporation | $18.15 | 2022 | |
| Esperion Therapeutics, INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Kommineni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.